Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Jurlique International

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and other activities related to therapeutic goods in Australia. This Act was introduced to address the need for a comprehensive framework to ensure that therapeutic goods available in Australia meet required safety, quality, and efficacy standards. Administered by the Therapeutic Goods Administration, which is part of the Department of Health, the Act aims to protect public health by controlling the quality and safety of therapeutic goods. One of its key objectives is to facilitate access to therapeutic goods that are safe and of high quality while also ensuring that manufacturers and suppliers comply with regulatory requirements. The Act provides the necessary legal basis for the regulation of therapeutic goods, including medicines, medical devices, and other health-related products, ensuring that they are appropriately monitored and managed to safeguard public health. On 7 December 2015, a delegate of the Secretary of the Department of Health granted consent under sections 14 and 14A of the Therapeutic Goods Act 1989 to Jurlique International Pty Ltd for the importation and supply of certain cosmetic products that did not fully comply with the labelling requirements stipulated in the Therapeutic Goods Order No. 69. Specifically, the consent allowed for the importation and supply of specified batches of SUN SPECIALIST SPF40 HIGH PROTECTION CREAM and PURELY WHITE SKIN BRIGHTENING DAY CREAM, which lacked the required batch number prefix on their container labels. This consent was granted to address a non-compliance issue while ensuring that the therapeutic goods in question were still of acceptable quality and safety standards, effective from 7 December 2015 until 30 September 2016.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products such as medicines, medical devices, blood and blood components, tissues, and cosmetics. The Act applies to entities and individuals involved in the importation, supply, manufacture, evaluation, and monitoring of these goods within Australia. This includes pharmaceutical companies, healthcare providers, and consumers. The jurisdictional reach of the Act is national, as it is a Commonwealth Act, and it extends its regulatory authority across all states and territories of Australia. The Therapeutic Goods Administration, an agency within the Department of Health, administers the Act and its subordinate instruments, which include regulations and orders that further define and refine the application of the Act. The Act may provide for exclusions or exemptions, such as for research or for goods used for personal purposes, but these must be clearly outlined in the relevant regulations or orders. In this instance, the consent granted under sections 14 and 14A of the Act to Jurlique International Pty Ltd pertains to specific products that do not conform to certain labelling requirements, allowing for their temporary importation and supply under specified conditions and timeframes.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 allow a delegate of the Secretary of the Department of Health to consent to certain activities concerning therapeutic goods that do not fully comply with the standards set out in Therapeutic Goods Orders. Specifically, these sections enable the consent for the importation and supply of goods that do not meet specific regulatory requirements, provided that such consent is granted under specific circumstances and for a limited period. In this case, the consent permits the importation and supply of certain batches of sunscreen and skin brightening cream that do not adhere to the batch number labelling requirements specified in the Therapeutic Goods Order No. 69. The obligations imposed by this consent are primarily on Jurlique International Pty Ltd, the applicant, and the Department of Health, the consenting authority. Jurlique International must ensure that the products in question are only imported and supplied within the timeframe specified by the consent, which is from 7 December 2015 until 30 September 2016. The Department of Health, as the consenting authority, must monitor compliance with the terms of the consent and ensure that the products do not enter the market beyond the authorised period or in any other manner not specified in the consent. Failure to comply with the terms and conditions of the consent, or the broader requirements of the Therapeutic Goods Act, may result in legal consequences. Under section 32 of the Act, the Therapeutic Goods Administration (TGA) has the authority to take enforcement actions against parties that breach the Act or associated regulations. Potential penalties for breaches can include fines, product recalls, and other corrective measures to prevent the distribution of non-compliant therapeutic goods. The maximum penalties for serious or repeated breaches can be substantial, reflecting the importance of ensuring that therapeutic goods meet safety, quality, and efficacy standards.